← Back to Search

Imaging

Cohort C for Alzheimer's Disease

N/A

Waitlist Available

Led By Yulin Ge, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 21 minutes

Awards & highlights

Study Summary

This trial is testing if measuring BBB disruption with MRI can help distinguish between normal and abnormal aging.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 21 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 21 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 21 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood-Brain Barrier (BBB) Permeability as Measured by GRASP DCE-MRI Sequence

Permeability Surface Area (PS) as Measured by GRASP DCE-MRI Sequence

Trial Design

3Treatment groups

Experimental Treatment

Group I: Cohort CExperimental Treatment3 Interventions

Amnestic mild cognitive impairment (aMCI) patients aged 65 and older. Participants in Cohort C will be matched by age and gender to participants in Cohort B. Participants in Cohort C will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 9 minutes of scan time.

Group II: Cohort BExperimental Treatment3 Interventions

Cognitively normal control participants aged 65 - 85 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.

Group III: Cohort AExperimental Treatment3 Interventions

Cognitively normal control participants aged 20 - 40 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Gadolinium-based Contrast Agent (GBCA) for MRI

2018

N/A

~30

3T Brain Scan

2018

N/A

~30

GRASP Dynamic Contrast-Enhanced (DCE) MRI

2018

N/A

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,367 Previous Clinical Trials

839,734 Total Patients Enrolled

Yulin Ge, MDPrincipal InvestigatorNYU Langone Health

1 Previous Clinical Trials

4 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research still have slots open for participants?

"Per clinicaltrials.gov, the medical trial is actively signing up participants. This research study was initiated on December 18th 2018 and revised last August 11st 2022."

Answered by AI

Are adults aged 18 and over eligible to join the research trial?

"Prospective participants in this research must be aged between 20 and 85. 23 trials are available for those below the age of majority, while a whopping 538 exist to benefit older adults above 65 years old."

Answered by AI

Who is eligible to join the experiment?

"Those who wish to participate in this Alzheimer's clinical trial must be between 20 and 85 years old. Sixty patients are required for the study to properly recruit its desired sample size."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

2018. "Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03389698.